Literature DB >> 3612208

The effect of intrathecal baclofen on electrical muscle activity in spasticity.

H Müller, J Zierski, D Dralle, U Börner, O Hoffmann.   

Abstract

The efficacy of intrathecally administered baclofen was demonstrated in three patients with different types of muscular hypertonia (supraspinal rigidity, spasms shortly after spinal trauma, spasms for many years induced by multiple sclerosis) using integrated electromyography. Reduction of muscular electrical activity was accompanied by clinical improvement during long-term infusion via an implanted pump. The three patients have been observed for more than 1 year, during which time the antispastic activity of intrathecally infused baclofen has remained stable. Intrathecal application of baclofen may be considered as a possible alternative to surgery.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612208     DOI: 10.1007/bf00314294

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

1.  A new agent for the control of spasticity.

Authors:  R F Jones; D Burke; J E Marosszeky; J D Gillies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-08       Impact factor: 10.154

2.  Observations on the circulation of the cerebrospinal fluid.

Authors:  G Di Chiro
Journal:  Acta Radiol Diagn (Stockh)       Date:  1966

3.  Rhythmic patterns of motor activity after lesions of the central nervous system in man.

Authors:  F Schepelmann
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

4.  Results of selective posterior rhizotomy in the treatment of painful and spastic paraplegia secondary to multiple sclerosis.

Authors:  M Sindou; M F Millet; J Mortamais; M Eyssette
Journal:  Appl Neurophysiol       Date:  1982

5.  A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.

Authors:  C Smolenski; S Muff; S Smolenski-Kautz
Journal:  Curr Med Res Opin       Date:  1981       Impact factor: 2.580

6.  Ratio of maximum H reflex to maximum M response as a measure of spasticity.

Authors:  W B Matthews
Journal:  J Neurol Neurosurg Psychiatry       Date:  1966-06       Impact factor: 10.154

7.  Continuous intrathecal baclofen for severe spasticity.

Authors:  R D Penn; J S Kroin
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

8.  Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.

Authors:  N Hassan; D L McLellan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-12       Impact factor: 10.154

9.  Human motor activity in decerebrate states and their sequelae.

Authors:  F Schepelmann
Journal:  Acta Neurochir (Wien)       Date:  1979       Impact factor: 2.216

10.  Tizanidine in the treatment of spasticity.

Authors:  P M Newman; M Nogues; P K Newman; D Weightman; P Hudgson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more
  7 in total

Review 1.  Imaging evaluation of intrathecal baclofen pump-catheter systems.

Authors:  A C Miracle; M A Fox; R N Ayyangar; A Vyas; S K Mukherji; D J Quint
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-28       Impact factor: 3.825

2.  Trends in the pathophysiology and pharmacotherapy of spasticity.

Authors:  J Noth
Journal:  J Neurol       Date:  1991-06       Impact factor: 4.849

3.  Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.

Authors:  G Ochs; A Struppler; B A Meyerson; B Linderoth; J Gybels; B P Gardner; P Teddy; A Jamous; P Weinmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

Review 4.  Spasticity and drug therapy.

Authors:  E W Wuis
Journal:  Pharm Weekbl Sci       Date:  1987-10-16

5.  Intraspinal baclofen in the treatment of severe spasticity and spasms.

Authors:  J Sahuquillo; T Muxi; M Noguer; R Jodar; C Closa; E Rubio; L Garcia-Fernandez; J M Guitart
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

6.  Delta-aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system.

Authors:  M Schwarz; T Klockgether; U Wüllner; L Turski; K H Sontag
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

7.  Intrathecal baclofen: Its effect on symptoms and activities of daily living in severe spasticity due to spinal cord injuries: A pilot study.

Authors:  Yogendrasinh Jagatsinh
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.